LGALS1 and neoplasm: Glycome remodeling of the EC surface facilitated binding of galectin-1 to N-glycans expressed on VEGFR-2 in anti-VEGF refractory tumors but inhibited galectin-1 binding in anti-VEGF sensitive tumors, which explains the proliferation of certain tumor types during anti-VEGF treatment [119].